BioSpace News Archive

Evofem Biosciences, Inc. , (OTCQB: EVFM) (the “Company”) today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash flow break even by year-end 2023.

Model N, Inc. released a new commissioned study by Forrester Consulting that shows how improved channel data management leads to better trust, collaboration, and bottom-line results.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial.

Procyrion, Inc. announced that use of its Aortix™ percutaneous mechanical circulatory support device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure and worsening renal function, which is known as cardiorenal syndrome.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (“RCC”), today reported its financial and operating results for the year ended December 31, 2022.

Presidio Medical, Inc. announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer.

Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced four poster presentations from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 2023 American Association for Cancer Research (AACR) Annual Meeting that will take place in Orlando, Florida on April 14-19.

Predictive Oncology Inc. (Nasdaq: POAI), Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update.

Karuna Therapeutics, Inc. announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share.

Jacobio Pharma announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combination of Jacobio’s CD73 monoclonal antibody JAB-BX102 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA®.